Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases

I. Caroline Crocker, Robert G. Townley

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Cyclic adenosine monophosphate (cAMP) is thought to be associated with inflammatory cell activity: high levels tend to decrease proliferation and cytokine secretion, whereas low concentrations have the opposite effect (1). Since many phosphodiesterases (PDEs) degrade cAMP, inhibitors of this enzyme decrease inflammatory cell activity. Theophylline, which has nonselective PDE inhibitor activity in addition to its other mechanisms of action, has been used in the treatment of asthma for many years. Unfortunately, because of the important role of PDEs in the cell, nonspecific inhibition of these enzymes causes many undesirable side effects. The discovery of PDE isoenzyme families (PDE1-PDE10), their subtypes (HPDE4 and LPDE4) and their differential distribution among the cell types, as well as their specific functions in controlling cell processes, has led to the development of new, specific PDE4 inhibitors. This review details the rationale for the use of PDE4 inhibitors in the treatment of allergic disease. In addition, the effects of PDE4 inhibitors in vitro, in preclinical animal models and in the clinic are covered. Finally, up-to-date information on the most recently developed inhibitors, such as SB-207499, CDP-840, AWD-12-281 and D-4418, is provided.

Original languageEnglish
Pages (from-to)519-535
Number of pages17
JournalDrugs of Today
Volume35
Issue number7
StatePublished - 1999

Fingerprint

Phosphodiesterase 4 Inhibitors
Phosphoric Diester Hydrolases
Cyclic AMP
Therapeutics
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Theophylline
Isoenzymes
Asthma
Animal Models
Cytokines
Enzymes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Crocker, I. C., & Townley, R. G. (1999). Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases. Drugs of Today, 35(7), 519-535.

Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases. / Crocker, I. Caroline; Townley, Robert G.

In: Drugs of Today, Vol. 35, No. 7, 1999, p. 519-535.

Research output: Contribution to journalReview article

Crocker, IC & Townley, RG 1999, 'Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases', Drugs of Today, vol. 35, no. 7, pp. 519-535.
Crocker, I. Caroline ; Townley, Robert G. / Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases. In: Drugs of Today. 1999 ; Vol. 35, No. 7. pp. 519-535.
@article{32ea7286cf1844719bc7074599b55563,
title = "Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases",
abstract = "Cyclic adenosine monophosphate (cAMP) is thought to be associated with inflammatory cell activity: high levels tend to decrease proliferation and cytokine secretion, whereas low concentrations have the opposite effect (1). Since many phosphodiesterases (PDEs) degrade cAMP, inhibitors of this enzyme decrease inflammatory cell activity. Theophylline, which has nonselective PDE inhibitor activity in addition to its other mechanisms of action, has been used in the treatment of asthma for many years. Unfortunately, because of the important role of PDEs in the cell, nonspecific inhibition of these enzymes causes many undesirable side effects. The discovery of PDE isoenzyme families (PDE1-PDE10), their subtypes (HPDE4 and LPDE4) and their differential distribution among the cell types, as well as their specific functions in controlling cell processes, has led to the development of new, specific PDE4 inhibitors. This review details the rationale for the use of PDE4 inhibitors in the treatment of allergic disease. In addition, the effects of PDE4 inhibitors in vitro, in preclinical animal models and in the clinic are covered. Finally, up-to-date information on the most recently developed inhibitors, such as SB-207499, CDP-840, AWD-12-281 and D-4418, is provided.",
author = "Crocker, {I. Caroline} and Townley, {Robert G.}",
year = "1999",
language = "English",
volume = "35",
pages = "519--535",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "7",

}

TY - JOUR

T1 - Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases

AU - Crocker, I. Caroline

AU - Townley, Robert G.

PY - 1999

Y1 - 1999

N2 - Cyclic adenosine monophosphate (cAMP) is thought to be associated with inflammatory cell activity: high levels tend to decrease proliferation and cytokine secretion, whereas low concentrations have the opposite effect (1). Since many phosphodiesterases (PDEs) degrade cAMP, inhibitors of this enzyme decrease inflammatory cell activity. Theophylline, which has nonselective PDE inhibitor activity in addition to its other mechanisms of action, has been used in the treatment of asthma for many years. Unfortunately, because of the important role of PDEs in the cell, nonspecific inhibition of these enzymes causes many undesirable side effects. The discovery of PDE isoenzyme families (PDE1-PDE10), their subtypes (HPDE4 and LPDE4) and their differential distribution among the cell types, as well as their specific functions in controlling cell processes, has led to the development of new, specific PDE4 inhibitors. This review details the rationale for the use of PDE4 inhibitors in the treatment of allergic disease. In addition, the effects of PDE4 inhibitors in vitro, in preclinical animal models and in the clinic are covered. Finally, up-to-date information on the most recently developed inhibitors, such as SB-207499, CDP-840, AWD-12-281 and D-4418, is provided.

AB - Cyclic adenosine monophosphate (cAMP) is thought to be associated with inflammatory cell activity: high levels tend to decrease proliferation and cytokine secretion, whereas low concentrations have the opposite effect (1). Since many phosphodiesterases (PDEs) degrade cAMP, inhibitors of this enzyme decrease inflammatory cell activity. Theophylline, which has nonselective PDE inhibitor activity in addition to its other mechanisms of action, has been used in the treatment of asthma for many years. Unfortunately, because of the important role of PDEs in the cell, nonspecific inhibition of these enzymes causes many undesirable side effects. The discovery of PDE isoenzyme families (PDE1-PDE10), their subtypes (HPDE4 and LPDE4) and their differential distribution among the cell types, as well as their specific functions in controlling cell processes, has led to the development of new, specific PDE4 inhibitors. This review details the rationale for the use of PDE4 inhibitors in the treatment of allergic disease. In addition, the effects of PDE4 inhibitors in vitro, in preclinical animal models and in the clinic are covered. Finally, up-to-date information on the most recently developed inhibitors, such as SB-207499, CDP-840, AWD-12-281 and D-4418, is provided.

UR - http://www.scopus.com/inward/record.url?scp=0032854108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032854108&partnerID=8YFLogxK

M3 - Review article

C2 - 12973397

AN - SCOPUS:0032854108

VL - 35

SP - 519

EP - 535

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 7

ER -